Tagged with China

China 2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland China, listing last year. The average amount of funds raised by these was a whopping four to five times higher…

China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, shares his perspectives on the growth of China’s Life Sciences and Healthcare market, the strong presence of Deloitte within China as a consulting firm, the recent trends of the market and their commitment to delivering comprehensive solutions to…

China PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the interviews and found the following recurring themes at the top of these executives’ minds.   “Patients” One recurring theme throughout the interviews was a stated commitment to patients. Many of these…

China As patients and consumers grow more educated and proactive in managing their own health and wellbeing, new ventures are hoping to serve their needs in not just prophylactic but also preventative health. HiNounou is a nifty little start-up based in Shanghai seeking to redefine the health management app.   Health…

China On 26 August 2019, the Chinese legislature, the National People’s Congress (NPC), passed the new Drug Administration Law (DAL), which came into effect on 1 December 2019 and represents one of the most important milestones for the Chinese healthcare industry. This is only the second systematic and structural major revision…

China GemPharmatech is a fast-growing service center for production, distribution and phenotyping of gene-modified mouse models with multiple subsidiaries in China, and an upcoming one in the USA. Chairman Professor Xiang Gao discusses the company’s story, its ambitions in China and globally, its recent Series A financing round, and its close…

Report PharmaBoardroom had the opportunity to sit down with over six hundred key stakeholders in the life sciences industry across fifteen different countries in 2019. The culmination of time spent in these countries and the insights gained from the interviews we conducted resulted in the publishing of thirteen country reports. Here…

China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…

China According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the biggest threats to global health, food security, and development today. If this trend is not slowed or reversed, it could jeopardize many, if not most, of our medical advancements to date. Antimicrobials are essential for the prevention and…

China Within the industry, Allergan already stands out for the interesting composition of its portfolio. For China President White Wang, this was precisely the attraction. He enthuses, “Allergan is truly a very unique company. It is at once a pharma company, a medical device company, a cosmetics/aesthetics company and a digital…

China The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market has been left playing catch-up. As the Chinese government looks to streamline its regulatory approval processes, MNCs plan to expand…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…